Tripping to Cope: Coping Strategies and Use of Hallucinogens during the COVID-19 Pandemic in Three Cultural Contexts
Genís Ona, Dóra Révész, Maja Kohek, Giordano Novak Rossi, Juliana Mendes Rocha, Rafael G. Dos Santos, Jaime E. C. Hallak, Miguel Ángel Alcázar‐córcoles, José Carlos Bouso
Psychoactives September 2, 2022 DOI: 10.3390/psychoactives1010003 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 2,971 |
| Population | Adults from English, Spanish, and Portuguese cultural contexts |
| Duration | Six-month follow-up |
| Keywords | Hallucinogen Coping psychology Disengagement theory Pandemic Distress Stressor Clinical psychology Developmental psychology Disease |
| Citations | 9 |
| Key findings | Coping strategies are more strongly related to psychological well-being and psychopathology than to hallucinogenic drug use, though hallucinogen users show an adaptive coping pattern with higher problem-focused engagement and disengagement and lower wishful thinking. |
Abstract
The COVID-19 pandemic has made evident the need to develop effective strategies to cushion the psychological consequences of social catastrophes. Preliminary evidence suggests that the use of hallucinogens is a protective factor that mitigates against such stressors. However, the underlying mechanisms must be further explored. This study specifically focused on the potential role of coping strategies in this regard, analyzing them through an online survey completed by a total of 2971 subjects who were followed up with from the beginning of the COVID-19 pandemic until six months after baseline. The survey was published in three different cultures (English, Spanish, and Portuguese), allowing for the collection of data from three different cultural contexts. The results show that coping strategies were generally more related to psychological well-being and psychopathology than to hallucinogenic drug use. However, regarding the latter, users of hallucinogens had higher scores on problem-focused engagement and disengagement and lower scores on wishful thinking than non-users. Longitudinally, while most baseline coping scores were associated with psychological distress and the severity of psychological symptoms, some coping strategies were related to the use of hallucinogens. These results show an adaptive pattern of coping strategies among hallucinogen users. Further research should take into account that coping strategies are only marginally associated with hallucinogenic drug use. Other underlying mechanisms explaining the better adjustment of users of hallucinogens to pandemics should be explored.
Citations in the library
Cited by 7
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment Current Neuropharmacology January 5, 2024
- Ayahuasca-induced personal death experiences: prevalence, characteristics, and impact on attitudes toward death, life, and the environment Frontiers in Psychiatry December 19, 2023
- Associations between the use of psychedelics and other recreational drugs with mental health and resilience during the COVID-19 pandemic Frontiers in Psychiatry June 15, 2023
- Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic Scientific Reports September 11, 2023
- A new insight into ayahuasca's adverse effects: Reanalysis and perspectives on its mediating role in mental health from the Global Ayahuasca Survey (GAS). PLOS mental health 2025
and 2 more in the library
Cites 31
- Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports October 13, 2017
- Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors Journal of Psychopharmacology October 11, 2017
- Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports February 10, 2020
- Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers Biological Psychiatry April 26, 2014
- Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology December 27, 2017
and 26 more in the library